Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development Program
October 14 2020 - 7:00AM
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical
company committed to developing medicines that transform the lives
of people with rare neurological diseases, today announced it will
host an educational webinar on Thursday, October 22, at 1:00 p.m.
ET to review multiple aspects of Angelman syndrome, including its
biological mechanism, and the Company’s OV101 (gaboxadol)
development program. The webinar will feature external experts
discussing topics that includes the role of tonic inhibition,
treatment practice in Angelman syndrome, measurement scales and
what to expect from the pivotal Phase 3 NEPTUNE trial of OV101 in
Angelman syndrome.
Webinar Agenda & Presenters:
- Welcome and
IntroductionJeremy M. Levin, DPhil, MB BChir – Chairman and Chief
Executive Officer at Ovid Therapeutics
- Tonic Inhibition,
Angelman Syndrome, and OV101Matthew During, M.D., DsC, FACP, FRACP
– Founder of Ovid Therapeutics
- Treating a Patient
with Angelman SyndromeChristopher Keary, M.D. – Child, Adolescent
and Adult Psychiatrist, Massachusetts General Hospital for
Children
- The Importance of
Clinical Global Impressions of Improvement (CGI-I)Judith Jaeger,
Ph.D., MPA – President & Principal Scientist, CognitionMetrics,
LLC
- OV101 in Angelman
Syndrome, Clinical Results and What to Expect from NEPTUNEAmit
Rakhit, M.D., MBA – President and Chief Medical Officer
at Ovid Therapeutics
- Compelling Market
OpportunityJason Tardio – Chief Commercial Officer
at Ovid Therapeutics
Webinar Registration & InformationDate:
Thursday, October 22Time: 1:00 p.m. ET
The live webinar can be accessed on the Events &
Presentations section of the Company's website
at https://investors.ovidrx.com/news-events/presentations-events.
An archived replay will be available on the Company's website
following the live event.
About OV101 (gaboxadol)
OV101 (gaboxadol) is a delta (δ)-selective GABAA receptor
agonist in clinical development for the potential treatment of two
rare neurodevelopmental conditions: Angelman syndrome and Fragile X
syndrome. These receptors are thought to have a central role in
tonic inhibition, a key physiological process of the brain believed
to be a core pathophysiology underlying certain neurodevelopmental
disorders. We believe OV101 is the first and only investigational
drug to specifically target the disruption of tonic inhibition,
which is believed to be a central cause of many clinical deficits
in these disorders. OV101 has demonstrated in laboratory studies
and animal models to selectively activate the δ-subunit of
GABAA receptors and thereby modulate tonic inhibition.
Positive data from the Phase 2 STARS trial of OV101 in adults and
adolescents with Angelman syndrome was reported in 2018. Results of
a successful Phase 2 signal-finding trial of OV101 in individuals
with Fragile X syndrome (ROCKET) were reported in 2020. The Company
anticipates initial data from an ongoing pivotal Phase 3 trial in
Angelman syndrome (NEPTUNE) in Q4 2020. OV101 has received Rare
Pediatric Disease Designation from the FDA for the treatment of
Angelman syndrome and was granted Orphan Drug and Fast Track
designations for Angelman syndrome and Fragile X syndrome.
The European Commission (EC) has granted Orphan Drug
designation to OV101 for the treatment of Angelman syndrome. The
Company has licensed to Angelini Pharma the right to develop,
manufacture and commercialize OV101 for the treatment of Angelman
syndrome in the European Union and other countries in the
European Economic Area, and also in
Switzerland, Turkey, the United
Kingdom and Russia.
About Ovid TherapeuticsOvid Therapeutics Inc.
is a New York-based biopharmaceutical company using its
BoldMedicine® approach to develop medicines that transform the
lives of patients with rare neurological disorders. Ovid has a
broad pipeline of potential first-in-class medicines. The Company’s
most advanced investigational medicine, OV101 (gaboxadol), is
currently in clinical development for the treatment of Angelman
syndrome and Fragile X syndrome. Ovid is also developing OV935
(soticlestat) in collaboration with Takeda Pharmaceutical Company
Limited for the potential treatment of rare developmental and
epileptic encephalopathies (DEEs). For more information on Ovid,
please visit www.ovidrx.com.
Forward-Looking StatementsThis
press release includes certain disclosures that contain
“forward-looking statements,” including, without limitation,
statements regarding the potential benefits, clinical and
regulatory development and commercialization of OV101, the
likelihood that data will support future development, and the
association of data with treatment outcomes. You can identify
forward-looking statements because they contain words such as
“will,” “appears,” “believes” and “expects.” Forward-looking
statements are based on Ovid’s current expectations and
assumptions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that may differ materially from those
contemplated by the forward-looking statements, which are neither
statements of historical fact nor guarantees or assurances of
future performance. Important factors that could cause actual
results to differ materially from those in the forward-looking
statements include uncertainties in the development and regulatory
approval processes, and the fact that initial data from clinical
trials may not be indicative, and are not guarantees, of the final
results of the clinical trials and are subject to the risk that one
or more of the clinical outcomes may materially change as patient
enrollment continues and/or more patient data become available.
Additional risks that could cause actual results to differ
materially from those in the forward-looking statements are set
forth in Ovid’s filings with the Securities and Exchange Commission
under the caption “Risk Factors.” Such risks may be amplified by
the COVID-19 pandemic and its potential impact on Ovid’s business
and the global economy. Ovid assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
Contacts
Investors and Media:Ovid Therapeutics
Inc.Investor Relations & Public Relationsirpr@ovidrx.com
Or
Investors: Maeve Conneighton/Dawn Schottlandt
Argot Partnersovid@argotpartners.com(212) 600-1902
Media: Dan Budwick 1AB
dan@1abmedia.com
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Sep 2023 to Sep 2024